(1) Three months ended September 30, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance condition for certain executive's share ...

(2) Includes the write-down of leasehold improvements, right of use assets and/or other assets and exit costs associated with consolidation of certain facilities. (3) Includes gain on insurance ...

CEO Lawrence V. Bruno highlighted that "Core continued to execute its strategic plan of technology investments targeted to both solve client problems and capitalize on Core's technical and geographic ...

Lawrence V. Bruno: Good morning in The Americas. Good afternoon in Europe, Africa, and The Middle East. And good evening in Asia Pacific. We would like to welcome all of our shareholders, analysts, ...

(1) The year ended December 31, 2023 includes reversals of stock compensation expense previously recognized due to a change in probability of performance condition for certain executive's share awards ...

probability of performance condition for certain executive's share awards. (2) Three months ended June 30, 2025 and September 30, 2025 includes the write-down of inventory. (3) Three months ended June ...

due to a change in probability of performance conditions for certain executives' share awards. The year ended December 31, 2024 includes reversals of stock compensation expense previously recognized ...

HOUSTON, Feb. 4, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") reported fourth quarter 2025 revenue of $138,300,000 ...